Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) Director Kevin Reilly sold 2,932 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $25.13, for a total transaction of $73,681.16. Following the completion of the transaction, the director directly owned 5,368 shares of the company’s stock, valued at approximately $134,897.84. This represents a 35.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Stock Performance
Kestra Medical Technologies stock opened at $22.85 on Friday. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The stock has a market cap of $1.34 billion, a P/E ratio of -9.44 and a beta of 0.62. The firm’s fifty day moving average price is $25.34 and its 200-day moving average price is $22.71.
Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. On average, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Stock Report on KMTS
Key Headlines Impacting Kestra Medical Technologies
Here are the key news stories impacting Kestra Medical Technologies this week:
- Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
- Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
- Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
- Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
- Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.
Institutional Trading of Kestra Medical Technologies
A number of institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its holdings in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after buying an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. boosted its position in Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares during the period. Alliancebernstein L.P. grew its holdings in Kestra Medical Technologies by 13.7% in the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after acquiring an additional 179,885 shares during the last quarter. Eventide Asset Management LLC increased its position in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the period.
Kestra Medical Technologies Company Profile
Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.
The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.
Featured Stories
- Five stocks we like better than Kestra Medical Technologies
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
